Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. kidney function
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Kidney Function Articles & Analysis

41 news found

Lead Poisoning Awareness Campaign for Adults Launched by New York State Department of Health

Lead Poisoning Awareness Campaign for Adults Launched by New York State Department of Health

“Some of the health effects listed by the department due to lead exposure include decreased brain and kidney function, raised blood pressure, increased chances of having a heart attack or stroke, and for pregnant individuals, increased chances of a miscarriage and harm to a baby’s development before birth,” said Frank Selamie, President of CTSI. ...

ByCochrane & Associates, LLC


Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

Bayer to start Phase III study with finerenone in adults with chronic kidney disease and type 1 diabetes

“Despite progress in risk reduction in type 2 diabetes, chronic kidney disease in type 1 diabetes remains understudied, leaving a huge unmet need to reduce the risks of end-stage kidney disease and cardiovascular events. New strategies are needed to slow the rate of decline in kidney function, which is why this important ...

ByBayer AG


New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA

New real world study data on reduced risk of adverse kidney outcomes for Xarelto compared to VKA

In the prospective observational XARENO study, after a two year follow up period, Xarelto was associated with a reduced risk of adverse kidney outcomes and all-cause mortality in patients with non-valvular atrial fibrillation (NVAF) and advanced chronic kidney disease (CKD), compared to vitamin K antagonists (VKA) XARENO evaluated the impact of Xarelto in ...

ByBayer AG


Kidney and Pancreas Function Diagnostic Enzymes Are Now Available at Creative Enzymes

Kidney and Pancreas Function Diagnostic Enzymes Are Now Available at Creative Enzymes

Recently, Creative Enzymes launched kidney and pancreas function diagnostic enzymes for the global market. The primary function of the kidney is to eliminate waste and excess fluid from the blood by producing urine, while the pancreas is responsible for the production of digestive enzymes and insulins. ...

ByCreative Enzymes


Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results

Puzzle Medical to Present at AHA 2022 its First-in-Human Study Results

(PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). PMD announced it will present its first-in-human results for the ModulHeartTM in the following session during the American Heart Association (AHA) meeting held November 5–7, 2022 at the McCormick Place Convention Center in Chicago, IL: ...

ByPuzzle Medical Devices Inc.


Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1

The excess production of oxalate results in the deposition of calcium oxalate crystals in the kidneys and urinary tract and can lead to the formation of painful and recurrent kidney stones and nephrocalcinosis, which can progress to kidney failure. PH1 can also lead to oxalate deposition in multiple organs beyond the kidney, a ...

ByAlnylam Pharmaceuticals, Inc.


Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes

Bayer to present new cardiorenal data for Kerendia (finerenone) across a broad range of patients with early to late-stage chronic kidney disease and type 2 diabetes

Despite well-controlled blood glucose levels and blood pressure, many patients with CKD and diabetes still progress to loss of kidney function. New therapeutic strategies are needed to prevent further end-organ damage and slow patient’s rate of decline in kidney function. ...

ByBayer AG


Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeartâ„¢

Puzzle Medical to Present at TCT 2022 Its First-in-Human Study Results for the ModulHeartâ„¢

(PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). PMD announced it will present its first-in-human results for the ModulHeartTM in the following session during the Transcatheter Cardiovascular Therapeutics (TCT) meeting held September 16-19, 2022 at the Boston Convention and Exhibition Center in ...

ByPuzzle Medical Devices Inc.


Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update

Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study, reports disease-modifying profile for Short Term DSR and provides business update

DSR (Direct Sodium Removal) heart failure drug development: Completed enrollment in SAHARA I[i] with first-generation DSR product (“DSR 1.0”) – extending study with second-generation DSR product (“DSR 2.0”) to support US IND[ii] filing by year end Proof-of-concept delivered in diuretic-resistant heart failure patients with dramatic and durable improvements in ...

BySequana Medical NV


Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart

Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart

All patients experienced improvements in cardiac and kidney function. Additionally, the ModulHeart device was successfully deployed, activated, and removed, with no procedural or device-related complications. ...

ByPuzzle Medical Devices Inc.


Angiodroid turns 500!

Angiodroid turns 500!

The number 500 is associated, for Italian culture, with a famous car that has marked the history of evolution and progress. We are particularly attached to this number, today more than ever. In 2021, Angiodroid exceeded 500 injectors on the market, opening up to a new age: despite the difficult times given by the Covid-19 pandemic, Angiodroid reached this milestone, which marks a new beginning ...

ByAngiodroid Spa


CO2 whenever possible: the Malaysian experience

CO2 whenever possible: the Malaysian experience

Congrats to Dr. Ismazizi B. Zaharudin and to the team of Kuala Lumpur National Heart Center – Institut Jantung Negara – for choosing CO2 as a #first contrast agent, saving the renal function of their patients. Amazing job with 40 patients treated in just a few weeks! #angiodroid #theCO2injector #ACDA #academy #CO2angiography #CO2 #procedure #zerocontrast #angiography ...

ByAngiodroid Spa


AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients

“The ongoing study of posoleucel in kidney transplant patients has demonstrated a favorable, preliminary safety and tolerability profile and encouraging cell persistence to date. ...

ByKalaris


Aurinia Presents Data Demonstrating LUPKYNIS (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

Aurinia Presents Data Demonstrating LUPKYNIS (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations

“A treatment response meeting these proteinuria treatment targets increases the chance for better long-term kidney outcomes such as avoidance of kidney failure, dialysis or need for ...

ByAurinia Pharmaceuticals Inc.


Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress

Use of LUPKYNIS was safe and well tolerated in patients for up to three years of treatment, with no new safety signals In AURORA 2, long-term treatment with LUPKYNIS led to a clinically relevant preservation of kidney function in LN patients A pooled analysis from the AURA-LV and AURORA 1 studies, also presented at ERA, showed early treatment response to ...

ByAurinia Pharmaceuticals Inc.


Inversago Pharma presents data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress

Inversago Pharma presents data on INV-202 in Diabetic Nephropathy at the ERA 2022 Congress

More specifically, INV-202 reduced glomerular injury, renal fibrosis and injury to proximal tubular epithelial cells, and also preserved podocyte structure and function. In particular, there was a marked, dose-dependent reduction in albuminuria in this model of diabetes and associated kidney injury. “The study showed that treatment with INV-202 reduced the ...

ByInversago Pharma


CVRx Receives MR-Conditional Labeling Approval for its Barostim Heart Failure System

CVRx Receives MR-Conditional Labeling Approval for its Barostim Heart Failure System

Barostim works by stimulating baroreceptors - natural sensors in the body that tell the nervous system how to regulate heart, kidney and vascular function. These effects reduce the heart's workload and help it pump more efficiently, helping to improve the symptoms for patients with heart failure. ...

ByCVRx


New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population

New independent market research says 84% US healthcare professionals likely to use Orviglance imaging agent in target population

Ascelia Pharma today announced and welcomed the results of independent market research showing that 84% of healthcare professionals will likely use Orviglance for magnetic resonance imaging (MRI) in patients with cancer in the liver and reduced kidney function. The independently conducted survey asked 270 healthcare professionals in the US (radiologists, ...

ByAscelia Pharma AB


Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

Vertex Advances VX-147 Into Pivotal Clinical Development for People With APOL1-Mediated Kidney Disease

The company will evaluate the safety and efficacy of VX-147 in a single pivotal clinical trial designed to assess the impact of VX-147, on top of standard of care, on kidney function and proteinuria in people with AMKD. The primary endpoint of this study is reduction in the rate of decline of kidney function as measured by ...

ByVertex Pharmaceuticals


Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study

Ascelia Pharma successfully completes Orviglance Hepatic Impairment Study

Each severity group had 6 volunteers which was matched to a control group with normal hepatic function. Preliminary data indicate that Orviglance was well tolerated with no serious adverse events. ...

ByAscelia Pharma AB

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT